Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 27: 1724-1728, 1981;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burnam, M. H.
Right arrow Articles by Singh, B. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burnam, M. H.
Right arrow Articles by Singh, B. N.

Clinical Chemistry, Vol 27, 1724-1728, Copyright © 1981 by American Association for Clinical Chemistry

Increased inactive creatine kinase B protein in the plasma of patients with malignancy

MH Burnam, JL Barstis, CS Stern, DM Rose, MA Crouch, CM Haskell and BN Singh

Using a specific radioimmunoassay for enzymically inactive creatine kinase (EC 2.7.3.2) B protein (CK-Bi), we studied 139 patients with various malignancies. We found it to be increased in certain adenocarcinomas, including colorectal, lung, and prostate, as has also been reported for enzymically active CK-BB. Of 15 patients with leukemia or lymphomas with active disease, 12 also had increased values for CK-Bi in plasma. In these patients, concentrations of CK-Bi in plasma tended to correlate with disease activity, increasing with aggressive malignancy and decreasing on successful treatment. Thus, measurement of CK-Bi may constitute a sensitive means for detecting malignancy and, in certain subsets of patients, for monitoring therapeutic response.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American Association for Clinical Chemistry.